Game-Changing Advancements Are Transforming The Obesity Drug Market
Growing market for obesity drugs expected to reach $100B by 2030
Potential Game Changers in Obesity Drug Market
While injectable GIP/GLP-1 have garnered attention, leading companies acknowledge imperative of adopting novel drug development approaches.
differentiator. Source: BioSpace; Medical Marketing and Media (MM+M)
Major recent deals and acquisitions
NovoNordisk is at the forefront with 6 upcoming launches in the upcoming 5 years. EliLilly is making waves too, advancing the development of combinations and oral drugs. Other big pharma like AstraZeneca and Roche are recognizing the potential of the obesity drug market with deals and collaborations.
While injectable GIP/GLP-1 has garnered attention, leading companies acknowledge the imperative of adopting novel drug development approaches.
Related Insights & Outlooks
Migraine Key Catalysts for 2023
Atacana Group
•
June 1, 2023
While there is no cure for migraine, pharmaceutical companies continue to innovate to provide treatment options for patients suffering from migraine.
Novel and Emerging Treatments in Spinal Muscular Atrophy
Atacana Group
•
June 1, 2023
Marketed products are being evaluated for age expansion, dose increase, and in previously treated SMA patients
Antiviral Vaccines 2024 & 2025 Catalysts Report
Atacana Group
•
April 19, 2024
The Leading companies in the Antiviral Vaccine market, such as Pfizer, Moderna, GSK, and AstraZeneca are anticipating pivotal advancements, including regulatory milestones, clinical trial updates, and strategic product launches.
.avif)